ChiCTR2500101731 版本V1.0 版本创建时间2025/04/29 10:46:12 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500101731 

最近更新日期:

Date of Last Refreshed on:

2025-04-29 10:45:54 

注册时间:

Date of Registration:

2025-04-29 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于临床和关键基因数据的围术期脑卒中预测、防治体系的建立与应用

Public title:

Establishment and application of perioperative stroke prediction, prevention and treatment system based on clinical and key gene data

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于临床和关键基因数据的围术期脑卒中预测、防治体系的建立与应用

Scientific title:

Establishment and application of perioperative stroke prediction, prevention and treatment system based on clinical and key gene data

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张高峰 

研究负责人:

张高峰 

Applicant:

Gaofeng Zhang 

Study leader:

Gaofeng Zhang 

申请注册联系人电话:

Applicant telephone:

+86 186 6160 7191

研究负责人电话:

Study leader's telephone:

+86 186 6160 7191

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

exgalaxy@163.com

研究负责人电子邮件:

Study leader's E-mail:

exgalaxy@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

青岛市市南区东海中路5号青岛市市立医院麻醉科

研究负责人通讯地址:

青岛市市南区东海中路5号青岛市市立医院麻醉科

Applicant address:

Anesthesiology Department of Qingdao Municipal Hospital, No. 5, Donghai Middle Road, Shinan District, Qingdao

Study leader's address:

Anesthesiology Department of Qingdao Municipal Hospital, No. 5, Donghai Middle Road, Shinan District, Qingdao

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

青岛市市立医院

Applicant's institution:

Qingdao Municipal Hospital

研究负责人所在单位:

青岛市市立医院

Affiliation of the Leader:

Qingdao Municipal Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-KY-051(快)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

青岛市市立医院伦理委员会

Name of the ethic committee:

Ethics Committee of Qingdao Municipal Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-02-21 00:00:00

伦理委员会联系人:

于珊

Contact Name of the ethic committee:

Shan Yu

伦理委员会联系地址:

青岛市市南区东海中路5号

Contact Address of the ethic committee:

5 Donghai Road Middle, Shinan District, Qingdao, Shandong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 532 8890 5831

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

青岛市市立医院

Primary sponsor:

Qingdao Municipal Hospital

研究实施负责(组长)单位地址:

青岛市市南区东海中路5号

Primary sponsor's address:

5 Donghai Road Middle, Shinan District, Qingdao, Shandong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

Country:

China

Province:

Shandong

City:

单位(医院):

青岛市市立医院

具体地址:

市南区东海中路5号

Institution
hospital:

Qingdao Municipal Hospital

Address:

5 Donghai Road Middle, Shinan District

经费或物资来源:

市科技专项资金

Source(s) of funding:

Municipal Special Fund for Science and Technology

Target disease:

Perioperative Stroke

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

巢式病例-对照研究 

Study design:

Nested case-control study 

研究目的:

1) 选择亚甲基四氢叶酸还原酶(MTHFR)(C677T)rs1801133、MTHFR (A1298C)rs1801131、乙醛脱氢酶2(ALDH2) rs 671、载脂蛋白E(APOE) rs 429358、APOE526 rs 7412 及水通道蛋白4(AQP4)rs9951307脑卒中相关基因位点,分析其多态性在岛城PS高危人群中的频数分布; 2) 建立岛城麻醉手术患者临床资料联合关键基因多态性数据库; 3) 基于患者临床资料和关键基因多态性数据,构建PS多参数预测模型体系,建立PS防治体系。  

Objectives of Study:

1. Select stroke-related gene loci including methylenetetrahydrofolate reductase (MTHFR) (C677T) rs1801133, MTHFR (A1298C) rs1801131, aldehyde dehydrogenase 2 (ALDH2) rs671, apolipoprotein E (APOE) rs429358, APOE rs526 rs7412, and aquaporin 4 (AQP4) rs9951307, and analyze the frequency distribution of their polymorphisms in the high-risk population for perioperative stroke (PS) in Daocheng Island City. 2. Establish a database combining clinical data with key gene polymorphism data for anesthesia and surgical patients in Daocheng Island City. 3. Based on patients' clinical data and key gene polymorphism data, construct a multi-parameter prediction model system for PS and establish a PS prevention and treatment system.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

北方汉族;根据基于临床数据的PS预测模型,Stroke after surgery tool或Mobile web-based, cardiac, stroke mortality risk model,预测PS发生率≥1%的患者;预计麻醉手术时长≥2小时的择期手术患者;

Inclusion criteria

Northern Han Chinese; identify patients with a predicted incidence of perioperative stroke (PS) >=1% according to clinical data-based PS prediction models, such as the Stroke after Surgery tool or the Mobile web-based, cardiac, stroke mortality risk model; and select patients undergoing elective surgery with an expected anesthesia and surgery duration of >=2 hours.

排除标准:

口腔黏膜溃疡;口腔、咽部、舌肿瘤等;有出血倾向,采集口腔黏膜标本可能出血者;不能配合采集口腔黏膜脱落细胞者(如合并精神疾患或认知功能障碍);近一个月内参加过临床实验;未成年人、孕产妇及哺乳期妇女;伴有其他情况,研究者认为不适合入选的患者。

Exclusion criteria:

Oral mucosal ulcer; tumors of the oral cavity, pharynx, and tongue, etc.; individuals with a tendency to bleed or for whom collecting oral mucosal specimens may result in bleeding; those unable to cooperate with the collection of oral mucosal exfoliated cells (such as those with concurrent mental illness or cognitive impairment); individuals who have participated in clinical trials within the past month; minors, pregnant and lactating women; patients with other conditions deemed unsuitable for inclusion by the investigator.

研究实施时间:

Study execute time:

From 2025-02-21 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-05-06 00:00:00 To 2026-12-31 00:00:00  

干预措施:

Interventions:

组别:

前瞻性病例对照研究:病例组

样本量:

10

Group:

prospective case-control study:case group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

组别:

前瞻性病例对照研究:对照组

样本量:

990

Group:

prospective case-control study:Control Group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

组别:

回顾性巢式病例对照研究:病例组

样本量:

90

Group:

Retrospective nested case-control study: Case group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

组别:

回顾性巢式病例对照研究:对照组

样本量:

410

Group:

Retrospective nested case-control study: Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China 

Province:

Shandong 

City:

 

单位(医院):

青岛市市立医院 

单位级别:

三甲 

Institution
hospital:

Department of Anesthesiology, Qingdao Municipal Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

MTHFR(C677T)rs1801133、MTHFR(A1298C)rs1801131、ALDH2 rs671、APOE388 rs429358、APOE526 rs7412及AQP4rs9951307基因位点多态性

指标类型:

主要指标

Outcome:

Polymorphism of genetic locus:MTHFR(C677T)rs1801133,MTHFR(A1298C)rs1801131,ALDH2 rs671,APOE388 rs429358,APOE526 rs7412,and AQP4rs9951307

Type:

Primary indicator

测量时间点:

测量方法:

口腔拭子采集口腔黏膜脱落细胞

Measure time point of outcome:

Measure method:

Collection of oral mucosal exfoliated cells using an oral swab

指标中文名:

血同型半胱氨酸水平

指标类型:

次要指标

Outcome:

Blood Homocysteine Level

Type:

Secondary indicator

测量时间点:

测量方法:

收集静脉血

Measure time point of outcome:

Measure method:

Collection of venous blood

指标中文名:

血脂水平

指标类型:

次要指标

Outcome:

Blood Lipid Level

Type:

Secondary indicator

测量时间点:

测量方法:

收集静脉血

Measure time point of outcome:

Measure method:

Collection of venous blood

指标中文名:

颅脑扩散磁共振基于沿血管周围间隙弥散张量成像分析(DTI-ALPS)得到ALPS指数

指标类型:

次要指标

Outcome:

ALPS index obtained based on resonance imaging diffusion tensor imaging analysis along the perivascular space (DTI-ALPS) under brain diffusion magnetic

Type:

Secondary indicator

测量时间点:

测量方法:

颅脑扩散磁共振基于沿血管周围间隙弥散张量成像分析(DTI-ALPS)

Measure time point of outcome:

Measure method:

Diffusion Tensor Imaging Analysis along Perivascular Spaces based on Cranio-Cerebral Diffusion MRI (DTI-ALPS)

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

口腔黏膜脱落细胞

组织:

口腔黏膜

Sample Name:

Oral mucosal exfoliated cells

Tissue:

Oral mucosa

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文支持材料

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Surpporting materials for the artical

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病历记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-04-29 10:45:54